Longeveron Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LGVN Nasdaq 2836 longeveron.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Longeveron Inc.

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - Dec 29th, 2025 7:15 am
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - Dec 17th, 2025 7:15 am
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - Dec 3rd, 2025 7:15 am
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - Dec 2nd, 2025 7:15 am
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - Dec 1st, 2025 10:00 am
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - Nov 19th, 2025 7:15 am
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - Nov 12th, 2025 7:05 am
LGVN Looking Toward Commercialization - Nov 5th, 2025 5:10 am
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 4th, 2025 2:05 pm
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - Oct 28th, 2025 7:15 am
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect - Oct 27th, 2025 7:15 am
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - Oct 6th, 2025 7:15 am
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors - Oct 1st, 2025 2:05 pm
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa - Sep 22nd, 2025 7:15 am
Longeveron® Announces Key Leadership Updates - Sep 3rd, 2025 2:05 pm
Longeveron (LGVN) Secures Rights to Stem Cell Patent for Cardiac Treatment - Aug 29th, 2025 5:25 am
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Aug 20th, 2025 7:15 am
LGVN Focuses on Commercialization and Expanding Pipeline - Aug 14th, 2025 4:07 am
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - Aug 13th, 2025 2:05 pm
Longeveron Announces Closing Of Up To $17.5 Million Public Offering - Aug 11th, 2025 2:15 pm